Rapt stock full#
Get a full understanding of how RAPT Therapeutics, Inc. was incorporated in 2015 and is headquartered in South San Francisco, California. A stock valuation and forecasting report include rating, fair value assessment, return forecasts, market ratio-based valuations and comparable analysis. Find the latest RAPT Therapeutics, Inc., RAPT stock market data. and changed its name to RAPT Therapeutics, Inc. rapt's stock i trade, fornitore and effects, either together or Birmingham aforesaid, in order to authorise or object to the in parcels, by public. In addition, RAPT expects the underwriters to be granted a 30-day option to purchase up to an additional 18.75 million of its common stock on the same terms and conditions. The company was formerly known as FLX Bio, Inc. It is also pursuing a range of targets, including general control nonderepressible 2 and hematopoietic progenitor kinase 1 that are in the discovery stage of development. The average price target is 57.00 with a high. Among the underlying components of the Russell 3000 index, we saw noteworthy options trading volume today in Johnson Controls International plc, where a total of 18,984 contracts have traded so far, representing approximately 1.9 million underlying shares.
![rapt stock rapt stock](https://www.netcials.com/tools/phpgraphlib-master/image/nasdaq-last-6-months/RAPT-Therapeutics-Inc-stock-highest-weekly-price-last-6-months.png)
The company's lead inflammation drug candidate is RPT193 to selectively inhibit the migration of type 2 T helper cells into inflamed tissues. Based on 5 Wall Street analysts offering 12 month price targets for RAPT Therapeutics in the last 3 months. Notable Monday Option Activity: JCI, RAPT, VIAC Stock Options Channel Staff - Monday, November 29, 4:19 PM.
![rapt stock rapt stock](https://st2.depositphotos.com/4107269/5986/i/600/depositphotos_59862571-stock-photo-two-drawing-baby-girls-asian.jpg)
Rapt stock trial#
Its lead oncology drug candidate is FLX475, an oral small molecule C-C motif chemokine receptor 4 antagonist that is in the Phase 1/2 clinical trial to investigate as a monotherapy and in combination with pembrolizumab in patients with advanced cancer. RAPT Therapeutics, Inc., a clinical-stage immunology-based biopharmaceutical company, focuses on discovering, developing, and commercializing oral small molecule therapies for patients with unmet needs in oncology and inflammatory diseases.